Clinical Trial Update: Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating genetically modified stem cells with Irinotecan hydrochloride for recurrent high-grade gliomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Genetically Modified Stem Cells
• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Status: WITHDRAWN